Structure Therapeutics: Navigating Key Milestones Ahead

Structure Therapeutics (NASDAQ:GPCR) is in focus after my previous article in June 2022. The company is a potential GLP-1 play, with key milestones dead ahead. GPCR is a clinical-stage biopharmaceutical company developing novel therapies for diabetes and obesity.

Structure Therapeutics (NASDAQ: GPCR) has been in the spotlight following its previous article in June 2022, positioning itself as a potential player in the GLP-1 receptor agonist market. The company, a clinical-stage biopharmaceutical entity, is developing novel therapies for diabetes and obesity, with key milestones anticipated in the near future.

Nxera Pharma, a Tokyo-based biopharmaceutical company, recently announced an expanded drug discovery pipeline focusing on obesity and metabolic diseases. The pipeline includes an oral GLP-1 agonist program, developed independently from Pfizer’s discontinued PF-06954522, and six additional GPCR-targeted programs using their NxWave platform [1]. This pipeline strategy addresses long-term weight maintenance, obesity-related co-morbidities, and reduced side effects, aligning with Structure Therapeutics' focus on diabetes and obesity therapies.

Eli Lilly's Q2 2025 results underscore the growing importance of oral GLP-1 therapies in the obesity and diabetes market. The company's oral candidate, orforglipron, showed promising results in Phase 3 trials, achieving a 12.4% average weight loss over 72 weeks [2]. Lilly's focus on oral therapies and primary care settings could unlock significant market potential, with the obesity and diabetes therapies market projected to hit $48.84 billion by 2030.

Structure Therapeutics' position as a clinical-stage company developing novel therapies for diabetes and obesity places it in an advantageous position to capitalize on the growing demand for oral GLP-1 therapies. The company's pipeline strategy, focusing on GPCR targets, aligns with the broader trend in obesity drug development, which includes expanding beyond injectables and applying high-throughput, structure-based screening to accelerate discovery.

As Structure Therapeutics approaches key milestones in its GLP-1 receptor agonist program, investors and financial professionals should closely monitor the company's progress. The potential for oral GLP-1 therapies to disrupt the market, driven by convenience and scalability, positions Structure Therapeutics as a promising player in the obesity and diabetes revolution.

References:
[1] https://www.pharmtech.com/view/nxera-s-new-glp-1-and-gpcr-targeted-drug-programs-aim-to-advance-obesity-and-metabolic-disorder-therapies
[2] https://www.ainvest.com/news/eli-lilly-q2-2025-outperformance-orforglipron-pipeline-era-obesity-diabetes-therapies-2508/